MENU

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Garcia-Vidal, Carolina; Sanjuan, Gemma; Moreno-Garcia, Estela; Puerta-Alcalde, Pedro; Garcia-Pouton, Nicole; Chumbita, Mariana; Fernandez-Pittol, Mariana; Pitart, Cristina; Inciarte, Alexy; Bodro, Marta; Morata, Laura; Ambrosioni, Juan; Grafia, Ignacio; Me

CLINICAL MICROBIOLOGY AND INFECTION
2021
VL / 27 - BP / 83 - EP / 88
abstract
Objectives: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19). Methods: We performed an observational cohort study of all consecutive patients admitted for >= 48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records. Results: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes. Conclusions: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

AccesS level

Green published, Bronze, Green accepted

MENTIONS DATA